Investigating BCG resistance in bladder cancer to find new treatment options
Multi-scale analysis of Bacillus Calmette-Guérin (BCG) resistant tumor micro-environment in non-muscle invasive bladder cancer to identify novel therapeutic axis
This study is looking at why some people with non-muscle invasive bladder cancer don’t respond to the usual treatment with BCG, by examining their tumor samples to find clues that could help improve future treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11108450 on NIH RePORTER |
What this research studies
This research focuses on non-muscle invasive bladder cancer (NMIBC), which is a common type of bladder cancer. It aims to understand why some patients do not respond to the standard treatment with Bacillus Calmette-Guérin (BCG) by analyzing the tumor microenvironment before and after treatment. By using advanced techniques like single-cell and spatial sequencing, the study will create a detailed molecular map of the tumor environment to identify potential new therapeutic targets. Patients' tumor samples will be collected to explore the differences between those who respond to BCG and those who do not.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with high-risk non-muscle invasive bladder cancer who are undergoing BCG treatment.
Not a fit: Patients with muscle-invasive bladder cancer or those who are not receiving BCG treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies for patients with BCG-resistant bladder cancer.
How similar studies have performed: Previous research has shown promise in understanding tumor microenvironments and their role in treatment resistance, suggesting that this approach could yield valuable insights.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Song, Won-Min — Icahn School of Medicine at Mount Sinai
- Study coordinator: Song, Won-Min
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.